drugset / Trial / NCT00755781

Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation

NCT00755781

Phase 3 Completed 284 enrolled APT Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

A Phase III, multi-center, randomized, controlled study designed to demonstrate the efficacy and safety of Cyclosporine Inhalation Solution (CIS)in improving survival and preventing bronchiolitis obliterans syndrome (BOS) when given prophylactically to lung transplant recipients in addition to their standard immunosuppressive regimen.

Timeline

Start
2008-09
Primary completion
2011-09
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 300 mg Other